Abstract: Age-related macular degeneration (AMD) has now become the leading cause of blindness in western developed countries, and it has also become one of the major blinding diseases in elderly Chinese. The vast majority of AMD patients become blind due to the choroidal neovascularization (CNV). Targeted anti-VEGF therapy for angiogensis, like ranibizumab and aflibercept can reduce greatly the rate of blindness in AMD patients. In addition, with the further indepth study of the mechanism of angiogensis, it is expected to develop a number of drugs, including siRNA targeted for VEGF, VEGF receptor tyrosine kinase inhibitor(TKI), complement factor, chemokines, pigment epitheliumderived factor (PEDF), steroids, medications targeted for the multiple aspects of the signal pathway in neovascular, which will bring new hope for wet AMD patients.